
Generate Collection Print

## Search Results - Record(s) 21 through 30 of 30 returned.

- 21. 6774135. 10 Aug 01; 10 Aug 04. Method of enhancing lysosomal .alpha.-galactosidase A. Fan; Jian-Qiang, et al. 514/315: 435/208 514/277 514/281 514/317 546/219. A61K031/445 A61K031/435 C07D211/40 C12N009/40.
- Ti. 22. 6566099. 27 Jan 00; 20 May 03. Nucleic acid encoding a chimeric polypeptide. Selden; Richard F., et al. 435/69.8; 435/200 435/207 435/366 435/455 530/350 536/23.1 536/23.5 536/24.1. C12P021/04 C12N009/24 C07K001/00 C07H021/02 C07H021/04 .
- To 23. 6395884. 06 Apr 00; 28 May 02. Therapy for .alpha.-galactosidase a deficiency. Selden; Richard F., et al. 530/417; 435/455 435/6 435/69.1 435/69.8 435/70.1 530/350. C07K001/00 C07K014/00 C12N015/63 C12P021/06 C12P021/04.
- <sup>17</sup> 24. <u>6274597</u>, 01 Jun 98; 14 Aug 01. Method of enhancing lysosomal .alpha.-Galactosidase A. Fan; Jian-Qiang, et al. 514/315; .A61K031/445.
- 1. 25. 6248725. 23 Feb 99; 19 Jun 01. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction. Alison; Malcom R., et al. 514/44; 424/198.1 424/199.1 424/9.1 424/9.2 435/320.1 435/456 435/456 800/8 800/9. A01N043/04 A61K031/70 C12N015/00 C12N015/00 C12N015/09 C12N015/09.
- 26. 6083725. 12 Sep 97; 04 Jul 00. Tranfected human cells expressing human .alpha.-galactosidase A protein. Selden; Richard F., et al. 435/69.8; 435/208 435/320.1 435/366 435/367 435/368 435/369 435/371 435/372 435/372.1 435/372.2 435/372.3 435/455 536/23.2 536/23.4. C12N005/10 C12N005/08 C12N009/40 C12P021/02 .
- T. WO003086452A2, 04 Apr 03. 23 Oct 03. METHODS OF ENHANCING LYSOSOMAL STORAGE DISEASE THERAPY. ZHU, YUNXIANG, et al. A61K038/19; A61K038/20 A61K038/28 A61K038/30 A61K031/715 A61K031/573 A61K045/08.
- 28. WO 2007121443 A2. New composition comprising a purified population of human fetal blood multi-lineage progenitor cells (MLPC) or its clonal line and a differentiation medium, useful in treating diseases, e.g., lysosomal storage diseases. BERGER M J, et al.
- √ 29. WO 0197829 A2. Use of a combination of enzyme replacement therapy, gene therapy and small molecule therapy for treating lysosomal storage disease e.g. Fabry disease. CHENG S H, et al.
- 30. CA 2272055 A1. New glucocerebrosidase (Gcc) DNA molecule modified in at least one nucleotide, useful in gene therapy or enzyme replacement therapy, particularly in treating Gaucher disease. CALLAHAN J W, et al.



Prev Page Next Page Go to Doc#